RDOR3 · B3 · Hospitals
Rede D’Or
We own 42 shares · in the portfolio for 5 days
- Since we bought
- −10.3%
- Ibovespa, same period
- −4.4%
At the close of 30 Oct 2026. Includes dividends declared since purchase.
Why we own it
Long-term demand for healthcare and a leading position. We pay a premium for quality.
What could go wrong
- Hospital margins fall.
- Claims rise at its health insurer.
What would make us sell
Written before we bought. A falling price is not on this list.
- Hospital margins or insurer claims worsen for two quarters in a row.
Twelve months against the Ibovespa
| Date | Rede D’Or | Ibovespa |
|---|---|---|
| 31 Oct 2025 | 0.0% | 0.0% |
| 5 Nov 2025 | +1.0% | +2.5% |
| 10 Nov 2025 | +7.7% | +3.8% |
| 13 Nov 2025 | +6.9% | +5.1% |
| 18 Nov 2025 | +4.0% | +4.7% |
| 24 Nov 2025 | +4.9% | +3.8% |
| 27 Nov 2025 | +6.3% | +5.9% |
| 2 Dec 2025 | +7.2% | +7.7% |
| 5 Dec 2025 | +1.8% | +5.2% |
| 10 Dec 2025 | +1.8% | +6.4% |
| 15 Dec 2025 | +8.7% | +8.7% |
| 18 Dec 2025 | +5.0% | +5.6% |
| 23 Dec 2025 | +4.5% | +7.3% |
| 30 Dec 2025 | +1.9% | +7.7% |
| 6 Jan 2026 | +6.6% | +9.4% |
| 9 Jan 2026 | +3.3% | +9.2% |
| 14 Jan 2026 | +1.2% | +10.4% |
| 19 Jan 2026 | +1.5% | +10.2% |
| 22 Jan 2026 | +8.9% | +17.4% |
| 27 Jan 2026 | +9.4% | +21.7% |
| 30 Jan 2026 | +6.3% | +21.3% |
| 4 Feb 2026 | +4.5% | +21.5% |
| 9 Feb 2026 | +5.8% | +24.5% |
| 12 Feb 2026 | +6.4% | +25.6% |
| 19 Feb 2026 | +12.0% | +26.1% |
| 24 Feb 2026 | +9.1% | +28.1% |
| 27 Feb 2026 | +1.1% | +26.2% |
| 4 Mar 2026 | −1.4% | +24.0% |
| 9 Mar 2026 | −3.3% | +21.0% |
| 12 Mar 2026 | −6.5% | +19.9% |
| 17 Mar 2026 | −6.8% | +20.6% |
| 20 Mar 2026 | −6.6% | +17.8% |
| 25 Mar 2026 | −1.1% | +24.0% |
| 30 Mar 2026 | −4.7% | +22.1% |
| 2 Apr 2026 | +0.1% | +25.8% |
| 8 Apr 2026 | +2.2% | +28.5% |
| 13 Apr 2026 | +4.9% | +32.4% |
| 16 Apr 2026 | −1.2% | +31.6% |
| 22 Apr 2026 | −2.7% | +29.0% |
| 27 Apr 2026 | −3.3% | +26.8% |
| 30 Apr 2026 | −3.4% | +25.3% |
| 6 May 2026 | +1.6% | +25.5% |
| 11 May 2026 | −9.5% | +21.6% |
| 14 May 2026 | −12.5% | +19.3% |
| 19 May 2026 | −14.2% | +16.5% |
| 22 May 2026 | −14.2% | +17.8% |
| 27 May 2026 | −13.4% | +17.5% |
| 1 Jun 2026 | −14.7% | +15.2% |
| 5 Jun 2026 | −17.5% | +13.0% |
| 10 Jun 2026 | −18.2% | +12.8% |
| 15 Jun 2026 | −14.9% | +14.0% |
| 18 Jun 2026 | −16.3% | +12.5% |
| 23 Jun 2026 | −13.6% | +14.5% |
| 26 Jun 2026 | −12.2% | +15.9% |
| 1 Jul 2026 | −11.5% | +14.8% |
| 6 Jul 2026 | −11.5% | +15.3% |
| 9 Jul 2026 | −11.1% | +15.5% |
| 14 Jul 2026 | −8.9% | +18.1% |
| 17 Jul 2026 | −9.5% | +16.2% |
| 22 Jul 2026 | −12.8% | +18.7% |
| 27 Jul 2026 | −15.0% | +17.2% |
| 30 Jul 2026 | −13.0% | +18.5% |
| 4 Aug 2026 | −13.0% | +19.0% |
| 7 Aug 2026 | −14.2% | +15.4% |
| 12 Aug 2026 | −17.9% | +12.0% |
| 17 Aug 2026 | −16.3% | +11.5% |
| 20 Aug 2026 | −14.7% | +12.3% |
| 25 Aug 2026 | −8.8% | +16.7% |
| 28 Aug 2026 | −10.4% | +17.5% |
| 2 Sep 2026 | −6.1% | +23.8% |
| 8 Sep 2026 | −5.3% | +25.3% |
| 11 Sep 2026 | −4.9% | +25.2% |
| 16 Sep 2026 | −5.7% | +24.1% |
| 21 Sep 2026 | −3.6% | +24.8% |
| 24 Sep 2026 | −4.8% | +23.0% |
| 29 Sep 2026 | −4.8% | +22.9% |
| 2 Oct 2026 | +1.1% | +28.5% |
| 7 Oct 2026 | +12.7% | +36.6% |
| 13 Oct 2026 | +13.0% | +38.3% |
| 16 Oct 2026 | +8.1% | +37.4% |
| 21 Oct 2026 | +11.0% | +38.1% |
| 26 Oct 2026 | −11.1% | +18.1% |
| 29 Oct 2026 | −17.9% | +13.1% |
| 30 Oct 2026 | −19.6% | +12.3% |
Valuation
- Price to earningsPrice ÷ last 12 months’ earnings per share
- 15.0×
- Price to bookPrice ÷ equity per share
- 3.5×
- EV to EBITDA
- 6.2×
- PEG ratio
- 0.87
- Dividend yieldLast 12 months
- 13.3%
- Market value
- R$ 72.5 bn
Profitability
- Return on equity
- 23.3%
- Return on assets
- 4.4%
- Gross margin
- 23.1%
- EBITDA margin
- 22.3%
- Net margin
- 8.7%
Growth
- Revenue, latest quarter vs a year ago
- +9.4%
- Earnings, latest quarter vs a year ago
- +17.3%
- Revenue, last full year
- +10.2%
- Earnings, last full year
- +21.9%
Balance sheet
- Cash
- R$ 43.3 bn
- Total debt
- R$ 50.9 bn
- Net debt to EBITDA
- 0.6×
- Debt to equity
- 2.46
- Current ratio
- 2.91
Risk, last 12 months
- Total returnIncluding dividends
- −19.6%
- VolatilityAnnualised, daily returns
- 41%
- Largest fall from a peak
- −30.8%
- Beta to the Ibovespa1.0 moves with the index
- 1.29
- Below its 12-month high
- −33.2%
Dividends
- Paid per share, last 12 months
- R$ 4.2077
Five years of results
| Year | Revenue | Net income | Earnings per share | Equity | Return on equity |
|---|---|---|---|---|---|
| 2025 | R$ 55.7 bn | R$ 4.8 bn | R$ 2.12 | R$ 21.6 bn | 22.4% |
| 2024 | R$ 50.6 bn | R$ 3.9 bn | R$ 1.73 | R$ 26.7 bn | 14.7% |
| 2023 | R$ 46.5 bn | R$ 2.1 bn | R$ 0.91 | R$ 23.8 bn | 8.9% |
| 2022 | R$ 23.0 bn | R$ 1.3 bn | R$ 0.53 | R$ 23.1 bn | 5.5% |
| 2021 | R$ 20.4 bn | R$ 1.7 bn | R$ 0.80 | R$ 14.7 bn | 11.4% |
Annual consolidated statements as reported to the CVM, via brapi.
Company profile
- Sector
- Saúde
- Industry
- Serviços Médicos Hospitalares
- Employees
- 67,285
- Website
- www.rededorsaoluiz.com.br/
Data as of the close of 30 Oct 2026. Market data from brapi.dev; financial statements as filed with the CVM. Ratios are provider estimates and may differ from company reports.